CircuLex CML/Nε-(Carboxymethyl)lysine ELISA Kit

CircuLex CML/Nɛ-Carboxymethyl)lysine ELISA Kit.



The CycLex Research Product CircuLex CML/Nε-(Carboxymethyl)lysine ELISA Kit is used for the quantitative measurement of CML-adducts in mammalian serum. It can be used for 96 Assays.

Target: CML/Nε-(Carboxymethyl)lysine
Product Type: ELISA Kit
Size: 96 Assays
Application: ELISA
Research Area / Disease: Metabolism
Sensitivity: The limit of detection (defined as such a concentration of CML-HSA giving absorbance lower than mean absorbance plus three standard deviations of the absorbance of Blank: Blank + 3SD Blank) is better than 0.063 µg/mL of sample.
Measurement Range: The measurement range is 0.109 µg/mL to 7.0 µg/mL. Any sample reading lower than the highest standard should be diluted with Dilution Buffer in higher dilution and re-assayed. Dilution factors need to be taken into consideration in calculating the CML-HSA concentration.
Regulatory Statement: For Research Use Only. Not for use in diagnostic procedures.


  • CML-BSA coated Microplate
  • 10X Wash Buffer
  • Sample Dilution Buffer
  • Standard Dilution Buffer
  • CML-HSA Standard
  • Primary Antibody
  • HRP conjugated Detection Antibody
  • Substrate Reagent
  • Stop Solution


  1. Aoki C et al. Advanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophy. Lab Invest. 93, 1170-83 (2013),
  2. Bao W et al. Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: possible role in diabetic complications. Am J Physiol Cell Physiol. 299, C1212-C1219 (2010),
  3. Boschetto P et al. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest. 43, 562-9 (2013),
  4. Coughlan MT et al. Advanced Glycation Urinary Protein-Bound Biomarkers and Severity of Diabetic Nephropathy in Man. Am J Nephrol. 34, 347-355 (2011),
  5. Fujii EY, Nakayama M. The measurements of RAGE, VEGF, and AGEs in the plasma and follicular fluid of reproductive women: the influence of aging. Fertility and Sterility. 94, 694-700 (2010),
  6. Han D et al. Induction of receptor for advanced glycation end products by insufficient leptin action triggers pancreatic β-cell failure in type 2 diabetes. Genes Cells. 18, 302-14 (2013),
  7. Karimi J et al. Relationship between advanced glycation end products and increased lipid peroxidation in semen of diabetic men. Diabetes Res Clin Pract. 91, 61-6 (2011),
  8. Lance A et al. Apolipoprotein E4 Exaggerates Diabetic Dyslipidemia and Atherosclerosis in Mice Lacking the LDL Receptor. Diabetes. 60, 2285-2294 (2011),
  9. Machado-Lima A et al. Advanced glycated albumin isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene expression impairing ABCA-1-mediated reverse cholesterol transport. Diabetes Metab Res Rev. 29, 66-76 (2013),
  10. Machado-Lima A et al. In type 2 diabetes mellitus glycated albumin alters macrophage gene expression impairing ABCA1-mediated cholesterol efflux. J Cell Physiol. 230, 1250-7 (2014),
  11. Malarde L et al. Endurance training and insulin therapy need to be associated to fully exert their respective beneficial effects on oxidant stress and glycemic regulation in diabetic rats. Free Radic Res. 48, 412-9 (2014),
  12. Meloche J et al. RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol. 31, 2114-24 (2011),
  13. Moriyama T et al. Involvement of advanced glycation end-products, pentosidine and N-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats. Toxicology. 268, 89-97 (2010),
  14. Munesue S et al. Low-molecular weight fractions of Japanese soy sauce act as a RAGE antagonist via inhibition of RAGE trafficking to lipid rafts. Food Funct. 4, 1835-42 (2013),
  15. Nemoto S et al. Aminoguanidine normalizes ET-1-induced aortic contraction in type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats by suppressing Jab1-mediated increase in ET(A)-receptor expression.; Peptides. 33, 109-19 (2012),
  16. Pettersson C et al. LDL-associated apolipoprotein J and lysozyme are associated with atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome. J Intern Med. 269, 306-21 (2011),
  17. Tahara N et al. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther. 30, 42-8 (2012),
  18. Xianwen Yi et al. α-Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy. Journal of Diabetes and its Complications. 25, 193-201 (2011),
  19. Zuwa?a-Jagie??o J et al. Advanced oxidation protein products and inflammatory markers in liver cirrhosis: a comparison between alcohol-related and HCV-related cirrhosis. Acta Biochim Pol. 58, 59-65 (2011)
  20. Oh MJ et al. Prediction of CML contents in the Maillard reaction products for casein-monosaccharides model. Food Chem. 267, 271-276 (2018)


  1. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: Biochemistry 35: 8075 –8083,1996
  2. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: Biochemistry 34: 10872 –10878,1995
  3. Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, Ota Z, Araki N, Horiuchi S: Kidney Int 48: 517 –526,1995
  4. Suzuki D, Yagame M, Jinde K, Naka R, Yano N, Endoh M, Kaneshige H, Nomoto Y, Sakai H: J Diabetes Complications 10: 314 –319,1996
  5. Imai N, Nishi S, Suzuki Y, Karasawa R, Ueno M, Shimada H, Kawashima S, Nakamaru T, Miyakawa Y, Araki N, Horiuchi S, Gejyo F, Arakawa M: Nephron 76: 153 –160,1997
  6. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S: Diabetologia 40: 764 –769,1997
  7. Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K: Am J Pathol. 147: 654 –667,1995
  8. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S, Itabe H, Takano T: Atherosclerosis 141: 61 –75,1998
  9. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S: Atherosclerosis 142: 67 –77,1999
  10. Kislinger T, Fu C, Huber B, Qu W, Taguichi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: J Biol Chem 274: 31740 –31749,1999
Code CY-8066
Product Type ELISA Kit
Size 96 Assays
Application ELISA

Related Content:

Pathway Posters

AMPK Pathway

Pathway Posters


Pathway Posters

Regulation of eIF4E